Switch to E/C/FTC/TAF daily
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV/AIDS
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Trial Timeline
Apr 1, 2019 → Jul 1, 2021
NCT ID
NCT03251144About Switch to E/C/FTC/TAF daily
Switch to E/C/FTC/TAF daily is a phase 1/2 stage product being developed by Gilead Sciences for HIV/AIDS. The current trial status is completed. This product is registered under clinical trial identifier NCT03251144. Target conditions include HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction.
What happened to similar drugs?
3 of 5 similar drugs in HIV/AIDS were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03251144 | Phase 1/2 | Completed |
Competing Products
11 competing products in HIV/AIDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Metformin | Merck | Phase 2/3 | 34 |
| Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC | Gilead Sciences | Pre-clinical | 18 |
| Biktarvy + Symtuza | Gilead Sciences | Phase 3 | 40 |
| Truvada | Gilead Sciences | Approved | 43 |
| bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART) | Gilead Sciences | Approved | 35 |
| ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet | Gilead Sciences | Phase 2 | 35 |
| Emtricitabine and Tenofovir | Gilead Sciences | Approved | 39 |
| TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tablets | Gilead Sciences | Phase 3 | 47 |
| Maraviroc | Pfizer | Phase 1 | 29 |
| Efavirenz | Bristol Myers Squibb | Pre-clinical | 26 |
| Moxifloxacin + Placebo + Efavirenz | Bristol Myers Squibb | Phase 1 | 29 |